Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Faris

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Annals of Surgery|January 20, 2015
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerCristina R Ferrone, Giovanni Marchegiani, Theodore S Hong, et al.
Cancer Discovery|February 13, 2018
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i><sup>V600E</sup> Colorectal CancerMehlika Hazar-Rethinam, Marianna Kleyman, G Celine Han, et al.
Nature Cancer|June 17, 2024
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Nature Cancer|April 2, 2024
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
JAMA Oncology|May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Nature Medicine|November 21, 2019
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Annals of Surgery|January 20, 2015
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerCristina R Ferrone, Giovanni Marchegiani, Theodore S Hong, et al.
Cancer Discovery|February 13, 2018
Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i><sup>V600E</sup> Colorectal CancerMehlika Hazar-Rethinam, Marianna Kleyman, G Celine Han, et al.
Nature Cancer|June 17, 2024
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Nature Cancer|April 2, 2024
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancersEmilie A Chapeau, Laurent Sansregret, Giorgio G Galli, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
JAMA Oncology|May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Cancer Discovery|May 21, 2017
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal CancersCarl U Bialucha, Scott D Collins, Xiao Li, et al.
Nature Medicine|November 21, 2019
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, et al.
Pageof 4